Clinical Trials & Evidence: Real Science That Touches Real Lives
When you’re facing a chronic condition like Primary Biliary Cholangitis (PBC), it’s natural to want to know — does this medication really work? And is it safe enough to trust with your health over the long haul?
LuciSelade (seladelpar)’s story is backed by strong scientific research, but behind those numbers and charts are patients — people just like you — whose lives have been changed for the better. Let’s explore how the clinical trials translate into real-world hope and healing.
Phase III RESPONSE Trial: Proof That LuciSelade Makes a Difference
The Phase III RESPONSE trial was a large, carefully controlled study involving 193 adults with PBC who hadn’t found full relief with the standard treatment or couldn’t tolerate it. What happened during those 12 months is more than just data — it’s about giving people back a sense of normalcy.
- Patients who took LuciSelade saw significant drops in liver enzyme levels, especially alkaline phosphatase (ALP), a key indicator of liver health.
- Many participants experienced noticeable relief from relentless itching, a symptom that often disrupts sleep, mood, and daily comfort.
- Throughout the year-long study, the drug was well tolerated. Side effects were mild and similar to those who received a placebo.
Phase II Studies: Finding the Right Dose, Sustaining the Benefits
Before the big trial, smaller Phase II studies laid the groundwork. They tested different doses of seladelpar to figure out how much was just right for balancing effectiveness and safety.
- These earlier studies showed that higher doses brought greater improvements.
- Patients who took seladelpar regularly for up to a year reported steady improvements.
- Safety remained a priority, and the medication continued to show a gentle side effect profile.
Meta-Analyses: Putting It All Together
Looking at the big picture, meta-analyses combine results from multiple studies.
- These reviews confirmed that ALP levels consistently dropped with treatment.
- The effect on bilirubin levels, another important indicator, was less clear.
- Patients generally experienced moderate relief from itching.
Diagnosis & When LuciSelade Is Used: Understanding Your Journey
Getting a diagnosis of Primary Biliary Cholangitis (PBC) can feel confusing and even a little scary.
How Do Doctors Diagnose PBC?
PBC happens when your body’s immune system starts attacking the small bile ducts in your liver.
Doctors look at several clues together, including:
- Blood tests to check liver enzymes — especially ALP and bilirubin
- Special antibodies called anti-mitochondrial antibodies (AMAs)
- Imaging such as medical scans or a liver biopsy
When Does LuciSelade Come Into Play?
Most people with PBC start on ursodeoxycholic acid (UDCA), which helps improve bile flow. LuciSelade is for those who:
- Still have high liver enzyme levels despite taking UDCA
- Can’t take UDCA because of side effects
How Do Doctors Know LuciSelade Is Right for You?
Your doctor will take a close look at your test results, your symptoms like itching or fatigue, and how your liver is doing overall. They’ll also consider how you responded to other treatments. This way, they can decide if LuciSelade (seladelpar) is a good fit for you — a treatment tailored just to your needs.
